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Abstract Over 90% of all cancers are carcinomas,
malignancies derived from cells of epithelial origin. As
carcinomas progress, these tumors may lose epithelial
morphology and acquire mesenchymal characteristics
which contribute to metastatic potential. An epithelial-to-
mesenchymal transition (EMT) similar to the process
critical for embryonic development is thought to be an
important mechanism for promoting cancer invasion and
metastasis. Epithelial-to-mesenchymal transitions have
been induced in vitro by transient or unregulated activation
of receptor tyrosine kinase signaling pathways, oncogene
signaling and disruption of homotypic cell adhesion. These
cellular models attempt to mimic the complexity of human
carcinomas which respond to autocrine and paracrine sig-
nals from both the tumor and its microenvironment.
Activation of the epidermal growth factor receptor (EGFR)
has been implicated in the neoplastic transformation of
solid tumors and overexpression of EGFR has been shown
to correlate with poor survival. Notably, epithelial tumor
cells have been shown to be signiﬁcantly more sensitive to
EGFR inhibitors than tumor cells which have undergone an
EMT-like transition and acquired mesenchymal charac-
teristics, including non-small cell lung (NSCLC), head and
neck (HN), bladder, colorectal, pancreas and breast carci-
nomas. EGFR blockade has also been shown to inhibit
cellular migration, suggesting a role for EGFR inhibitors in
the control of metastasis. The interaction between EGFR
and the multiple signaling nodes which regulate EMT
suggest that the combination of an EGFR inhibitor and
other molecular targeted agents may offer a novel approach
to controlling metastasis.
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Introduction
Human cancers rely on multiple overlapping signal trans-
duction pathways to activate and regulate cellular
proliferation, survival and migration programs. The epi-
thelial-to-mesenchymal transition (EMT) is a critical
process in embryonic development for metazoan organisms
and a similar process has also been shown to play a role in
oncogenic progression and metastasis. Tumor metastasis
involves a sequential series of processes which promote
and regulate the escape of migratory cancer cells to gen-
erate metastatic lesions at distant sites. The process begins
in the primary tumor, where tumor cells dysregulate
homotypic cell adhesion, downregulate cell adhesion pro-
teins such as E-cadherin, and upregulate proteins
characteristic of a more motile, mesenchymal-like pheno-
type such as vimentin. This process requires transcriptional
reprogramming to suppress E-cadherin expression via
transcription factors associated with EMT (for review see
[1]). Tumor cells undergoing EMT have been shown to
undergo ‘‘cadherin switching’’, downregulating E-cadherin
and compensating with alternate cadherin proteins such as
N cadherin [2]. There is evidence that the downregulation
of E-cadherin and upregulation of proteins characteristic of
a mesenchymal phenotype may occur preferentially at the
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requires this initial disruption of cell–cell junctions and
gain of cellular motility, permitting individual cells to
migrate away from the primary tumor. In order to migrate
through the surrounding extracellular matrix (ECM) cells
may upregulate secreted proteases such as the matrix
metalloproteinases (MMPs). These motile, invasive cells
may then cross the endothelial cell barrier and intravasate
into the bloodstream. Once in the bloodstream, these
mesenchymal-like cancer cells can travel to distant sites
where they extravasate the endothelial cell wall to colonize
in a new, supportive niche. Primary tumor cells of speciﬁc
cellular origins have been shown to preferentially colonize
speciﬁc tissues, although the reasons for this are not
entirely clear. However it is commonly accepted that once
a metastatic tumor cell has implanted in a niche supportive
of proliferation, that cell may undergo a mesenchymal-to-
epithelial transition (MET). Consistent with this, the
emerging metastatic tumor often resembles the primary
tumor from which it derived both in cellular phenotype and
multi-cellular architecture. It is not clear whether EMT-like
changes are required for all steps in metastasis, and the
possibility remains that EMT is a necessary but insufﬁcient
step in cancer metastasis.
Cellular biomarkers of EMT
A hallmark of EMT is loss of E-cadherin, a key mediator of
cell–cell junctions. Numerous studies have shown a high
correlation between loss of E-cadherin, the gain of
vimentin and tumor invasiveness in cancer cells and patient
tumors (e.g. [4–6]). A down regulation of E-cadherin most
frequently results from transcriptional repression, mediated
by zinc ﬁnger, forkhead domain and bHLH factors
including Zeb1/TCF8/dEF1, Zeb2 (Sip1), Snail, Slug,
FOXC2 and Twist. The expression of Snail, Slug and
speciﬁc bHLH transcription factors have been implicated
in cell survival and acquired resistance to chemotherapy
[7–13]. However loss of E-cadherin alone does not con-
stitute EMT, as cells which harbor a mutation in E-
cadherin and have lost functional cell–cell junctions do not
acquire the additional morphological and transcriptional
changes associated with EMT [14, 15]. These changes
include acquisition of cellular markers characteristic of a
mesenchymal cell such as vimentin and ﬁbronectin,
expression of E-cadherin-repressing transcription factors,
and frequently the acquisition of a migratory or ‘‘scatter-
ing’’ morphology. Loss of E-cadherin appears to be a
prerequisite for tumor progression and not just a conse-
quence of tumor dedifferentiation. In transgenic mice
which spontaneously develop pancreatic tumors, E-cad-
herin expression was shown to decrease with tumor
progression, but maintenance of E-cadherin expression
during tumorigenesis arrested tumor development at the
benign adenoma stage while expression of a dominant
negative E-cadherin induced early metastasis [16]. Ectopic
expression of E-cadherin is sufﬁcient to suppress tumor cell
invasion in vitro and tumor progression in vivo while
knock-down of E-cadherin converts cells from non-inva-
sive to invasive [17]. However, ectopic expression of E-
cadherin does not restore an epithelial phenotype in cells
which overexpress the transcriptional repressor Twist [18].
This implies that restoration of E-cadherin to mesenchymal
cells may be insufﬁcient to reverse EMT and confer an
epithelial phenotype. Taken together, these observations
are consistent with the hypothesis that E-cadherin has a
tumor suppressive function and is not simply a marker of
tumor differentiation.
Accumulating evidence suggests that EMT occurs at the
level of transcriptional reprogramming and chromatin
remodeling [18–23]. Several transcription factors have been
implicated in the transcriptional repression of E-cadherin,
through interaction with speciﬁc E-boxes (reviewed in
[24]). The zinc ﬁnger proteins Snail, Slug, Zeb-1 and Zeb-2
(SIP1) as well as the bHLH factors Twist and E12/E47 have
been shown to repress E-cadherin and markers of cell
polarity. Ectopic expression of Twist or Zeb-1 is sufﬁcient
to downregulate endogenous E-cadherin and induce EMT
[18, 20, 25–27]. Snail has been shown to activate the tran-
scription of the mesenchymal biomarkers vimentin and
ﬁbronectin. Moreover, expression of Snail has been shown
to induce transcriptional downregulation of E-cadherin, to
upregulate vimentin, ﬁbronectin and Zeb1 and to promote a
ﬁbroblastic, invasive cellular phenotype [28]. The fact that
Zeb1 is activated by Snail implies cooperativity between
these factors although Zeb1 does not appear to be directly
downstream of Snail. Elegant in vivo and in vitro studies
using a series of breast carcinoma cell lines with distinct
metastatic properties identiﬁed Twist as a key regulator of
metastasis [18]. Overexpression of Twist in non-cancerous
epithelial cells induces expression of mesenchymal cell
markers, repression of E-cadherin and an EMT-like phe-
notype. Consistent with this, suppression of Twist inhibits
metastasis in a mouse mammary carcinoma model [18].
Cellular signals promoting EMT-like transitions
Activation of these transcription factors, leading to initia-
tion of EMT and consequently metastasis, may be triggered
by a variety of extra- and intracellular signals. One of the
ﬁrst factors observed to induce EMT was ‘‘scatter factor’’
or HGF [29, 30]. Since this early observation, a large
number signaling pathways have been shown to induce
EMT in vitro. These include growth factors (EGF, VEGF,
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integrin signaling, extracellular matrix proteins (MMPs),
inﬂammatory signals (COX-2), and potentially stress
stimuli such as hypoxia, signaling through non-receptor
tyrosine kinases such as Src and oncogenic activation of
receptor tyrosine kinases RTKs) [31–35]. These EMT-
activating signals can be paracrine, emanating from inﬁl-
trating stroma, or autocrine, produced by the tumor cells
themselves. One intriguing report suggests that EMT may
not only promote the migration of primary breast cancer
tumor cells, but may also lead to the formation of non-
malignant stromal cells, and this reciprocal interaction may
help explain the poor prognosis of some cancers which
show evidence of EMT [36].
In addition to effects on proliferation and migration,
EMT activators have been shown to promote cell survival
through inhibition of apoptosis. Interestingly, TGF-b has
been shown to be a potent activator of apoptosis in many
cell types including epithelial cells [37, 38]. When treated
with TGF-b, most fetal hepatocytes undergo apoptosis,
however a fraction survive. Those hepatocytes which have
survived TGF-b treatment, at least in part through resis-
tance to apoptosis, exhibit phenotypic and genomic
changes characteristic of an EMT, including increased
vimentin expression and higher levels of proto-oncogene
transcripts as well as elevated pAkt and Bcl-XL [39, 40].
EMT-like transitions have been also been shown to shown
to confer resistance to TGF-b induced apoptosis mammary
epithelial cells [41, 42]. Evidence from several independent
research groups suggests that the EMT-inducing tran-
scription factors Snail and Slug can induce expression of
anti-apoptotic genes while down-regulating pro-apoptotic
pathways in both epithelial cells and hematopoetic pro-
genitor cells [43–45]. This EMT-related inhibition of
apoptosis may provide selective advantage for tumor cells
which are transitioning to a mesenchymal-like state. The
activation of the PI3K/Akt cell survival pathway through
alternate RTKs may protect against TGF-b induced apop-
tosis while driving pathways critical to carcinogenesis.
RTKs, such as EGFR, c-Met, IGF-1R, FGF receptors and
the non-RTK c-Src have been reported to induce phos-
phorylation of E-cadherin and associated catenins, resulting
in their degradation [46], providing a link between onco-
genic activation of these kinases and induction of EMT.
Thus a rationale exists for the prevention of EMT-like
transitions and tumor metastasis through inhibition of these
oncogenic kinases in early-stage carcinomas.
IGF-1R signaling and EMT
Several lines of evidence implicate IGF-1R signaling as an
important driver of EMT. In mammary epithelial cells,
constitutively active IGF-IR caused cells to undergo EMT
which was associated with dramatically increased migra-
tion and invasion, and this transition was mediated by the
induction of Snail and downregulation of E-cadherin [47].
Multiple groups have demonstrated that IGF-1R activation
or overexpression correlates with increased invasion and
metastasis [48–51]. These effects are mediated, at least in
part, by its ligand, IGF-1. IGF-1 is known to inﬂuence cell
adhesion to the substratum and integrin-mediated cell
motility [52]. Furthermore, IGF-1 stimulation can induce
the phosphorylation and transcriptional activation of b-
catenin and dissociation of E-cadherin from the cell
membrane [53]. In addition to disruption of homotypic cell
adhesion, IGF-1 has also been shown to promote tumor
invasiveness via secretion of matrix metalloproteinases
[54] or crosstalk with integrin signaling pathways [55].
IGF-1R is ubiquitously expressed but is frequently
overexpressed in tumors, including melanomas, pancreas,
prostate and kidney (reviewed in [56]). Perhaps most rel-
evant is not the expression level of IGF-1R but its function
in cancer cells. IGF-1R signaling promotes Akt phos-
phorylation and protection from apoptosis, which is
predicted to limit the efﬁcacy of standard of care chemo-
therapies. Thus there is a strong rationale for development
of IGF-1R targeted therapies, and IGF-1R inhibition might
be expected to enhance the effect of cytotoxic chemo-
therapies or other molecular targeted therapies. Several
IGF-1R targeted therapeutics are currently in early clinical
trials. An array of monoclonal antibodies are currently in
Phase I or Phase II trials, including CP-753,871 (Pﬁzer),
AMG0479 (Amgen), R1507 (Genmab/Roche), IMC-A12
(Imclone), AVE-1642 (ImmunoGen/Sanoﬁ-Aventis),
MK0646 (Merck) and SCH717454 (Schering-Plough).
Two low molecular weight inhibitors of the IGF-1R tyro-
sine kinase have entered Phase I trials: OSI-906 (OSI
Pharmaceuticals) and INSM-18 (Insmed). Given the role of
IGF-1R signaling in cell survival and EMT, one might
hope that these therapies might target both the primary
tumor as well as emerging metastatic cells.
EGFR promotion of EMT-like transitions
EGFR function is frequently dysregulated in epithelial
tumors, and EGFR signaling has been shown to play an
important role both in cancer progression and in EMT-like
transitions. EGF has been shown to promote tumor cell
migration and invasion, at least in part through dephos-
phorylation and inactivation of FAK [57–60]. EGF
treatment of tumor cells overexpressing EGFR also leads to
downregulation of caveolin-1 which leads to loss of
E-cadherin, transcriptional activation of b-catenin and
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might be expected to restrain EMT in certain cellular
contexts. In support of this hypothesis, ligand-independent,
constitutively active forms of EGFR can increase motility
and invasiveness of tumor cells and EGFR inhibitors have
been shown to inhibit cancer cell migration in vitro [62–
65]. In oral squamous cell carcinoma cells EGFR inhibition
resulted in a transition from a ﬁbroblastic morphology to a
more epithelial phenotype as well as accumulation of
desmosomal cadherins at cell–cell junctions [66]. Taken
together, these summarized observations suggest that
inhibition of EGFR affects tumor growth through inhibiting
EGFR-dependent mitogenic stimulation but may also
restrain invasion and metastasis by re-establishing inter-
cellular contacts between tumor cells. Such inhibition of
EMT, and potentially metastasis, may translate to
improved overall patient survival in the clinical setting.
EGFR inhibitors in cancer therapy
EGFR is widely expressed by cells of both epithelial and
mesenchymal lineages, and the degree of EGFR expression
is variable [67]. EGFR overexpression has been reported in
multiple human cancers including non-small cell lung
(NSCLC), head and neck (HNSCC), pancreas, breast and
central nervous system (CNS), and has been shown to
correlate with poor survival [68]. Several selective EGFR
and Her family antagonists have been shown to offer
clinical beneﬁt, including erlotinib (OSI Pharmaceuticals/
Genetech/Roche), geﬁtinib (Astra Zeneca) and lapatinib
(GlaxoSmithKline). Erlotinib is approved for the treatment
of NSCLC patients who have failed two or three previous
rounds of chemotherapy. Erlotinib is also approved in the
USA and Europe for the treatment of pancreatic cancer in
combination with gemcitibine. Lapatinib, a dual inhibitor
of EGFR and Her2, has been shown to delay progression of
trastuzumab-refractory breast cancer and is used in com-
bination with capecitibine for patients who have received
prior therapy with an anthracycline, a taxane, and trast-
uzumab. Anti-EGFR antibodies have also shown clinical
utility, including cetuximab (Imclone/Bristol Myers) and
panitumamab (Abgenix/Amgen) which are approved for
the treatment of EGFR-expressing, metastatic colorectal
carcinoma. Additional small molecule dual EGFR-Her2
inhibitors which bind irreversibly are in earlier stages of
clinical development. The current EGFR inhibitors have
provided signiﬁcant clinical beneﬁt when compared to the
current standard of care, however not all patients derive a
beneﬁt in terms of overall survival or RECIST criteria. For
example, in the BR.21 trial which compared the efﬁcacy of
erlotinib as a single agent in comparison to placebo in
NSCLC patients who did not respond to chemotherapy, the
overall response rate was only 8.9% while the hazard ratio
for treatment beneﬁt associated with overall survival was
0.7 [69]. The median survival among patients who were
treated with erlotinib was 6.7 months compared to
4.7 months for those treated with placebo. These data
suggest both that RECIST did not directly correlate with
potential survival beneﬁt and that some, but not all,
patients clearly beneﬁted from erlotinib. This observation
spurred research to identify biomarkers to predict patient
response to erlotinib and potentially other EGFR antago-
nists, and to identify the mechanistic basis for the
differential response.
EMT and sensitivity to EGFR inhibitors
Parallel efforts from independent research groups
employed gene expression and proteomic proﬁling to
identify biomarkers which correlated with sensitivity to
erlotinib [70–72]. Each of these groups used panels of
established NSCLC cell lines and xenografts to determine
commonalities within those cell lines for which erlotinib
inhibited growth in vitro and in vivo, as compared to those
cell lines which were insensitive to erlotinib. Those cell
lines which were classiﬁed as sensitive, having greater than
50% maximal inhibition of proliferation, expressed the
canonical epithelial markers E-cadherin and c-catenin and
displayed the classic cobblestone epithelial morphology
and tight cell–cell junctions of epithelial cells. Conversely,
those cell lines which were relatively insensitive to erl-
otinib lacked those epithelial markers and expressed
proteins characteristic of mesenchymal cells, including
vimentin, ﬁbronectin and Zeb-1 and exhibited a more
ﬁbroblastic, scattered morphology. These changes are
consistent with cells which have undergone EMT. These
observations were later extended to other tumor types and
EGFR antagonists, including pancreatic, colorectal [5],
head and neck [73], bladder [74] and breast [75] suggesting
that EMT status may be a broadly applicable indicator of
sensitivity to EGFR inhibitors.
An important clinical substantiation of this hypothesis
resulted from a retrospective analysis of TRIBUTE, a
NSCLC phase III randomized trial which compared the
combination of erlotinib with chemotherapy to chemo-
therapy alone [76]. This trial failed to show signiﬁcant
clinical beneﬁt for the concurrent administration of erloti-
nib and chemotherapy, however subset analysis of
E-cadherin levels in patient samples using immunohisto-
chemistry was revealing. Patients with tumor samples
showing strong E-cadherin staining had a signiﬁcantly
longer time to progression (hazard ratio 0.37) and a
nonsigniﬁcant increase in overall survival when treated
with the combination of erlotinib and chemotherapy as
688 Clin Exp Metastasis (2008) 25:685–693
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of EGFR itself, as measured by IHC was a poor predictor
of response to EGFR antagonists, both in the clinic and in
cultured cell lines [70, 77]. Recent studies suggest that it is
not the abundance of receptor, but rather the activation of
the EGFR signaling axis that mediates sensitivity to EGFR
inhibition, at least in vitro [78–80]. Collectively, these
compelling in vitro data and clinical ﬁndings indicate that
expression of E-cadherin or vimentin, and EMT as a pro-
cess, may be viable biomarkers to predict efﬁcacy of EGFR
inhibitors in cancer patients. Clearly further clinical eval-
uation is warranted and is currently underway at multiple
sites.
Bypassing EGFR-dependent activation of PI3-kinase
and Ras pathways
The mechanism by which EMT results in insensitivity to
EGFR antagonists appears to derive from the acquisition of
alternative routes to activation of the PI3 kinase-Akt-
mTOR and Ras-Raf-Mek-Erk pathways. It has been
reported that cells which have transitioned to a mesen-
chymal-like state may have upregulated the PI3K-Akt cell
survival pathway to circumvent apoptosis [39], and con-
sequently have decreased sensitivity to an inhibitor of the
MAPK proliferative pathway. Human cancer cells which
exhibit mesenchymal characteristics express lower levels
of EGF ligands, suggesting that these cells have become
dependent upon alternate signaling pathways [71]. How-
ever fetal rat hepatocytes which have undergone TGF-b -
mediated EMT have upregulated EGFR ligand expression
[81], and in this system inhibition of EGFR does not block
TGF-b -mediated EMT [82]. Thus in fetal hepatocytes,
EGFR activation appears to be dispensable for the EMT
process, however in human cancer cells EGFR signaling is
an important driver of EMT. The expression EGFR and
reported downregulation of ligand in mesenchymal
NSCLC cells suggests that it is not the expression of the
growth factor receptor, but rather the usage of that receptor,
which governs sensitivity to targeted inhibitors. For
example it has been shown that Her3, a heterodimerization
partner of EGFR, allows EGFR to effectively activate the
PI3 kinase-Akt pathway [83]. It has also been shown that
Her3 RNA transcripts and protein are attenuated or lost
during EMT-like transitions, depriving EGFR of PI3 kinase
coupling [70, 80]. There is substantial evidence that cancer
cells can readily shift the cellular equilibrium to rely on
alternate growth factor and adhesion signaling pathways in
response to EMT-like transitions. For example, inhibition
of the Ras-MAPK proliferative pathway can lead to
increased activation of the PI3K-Akt cellular survival
pathway [75, 84, 85]. Therefore it is not surprising that
increased IGF-1R signaling has been associated with
insensitivity to EGFR inhibitors [86, 87]. High concentra-
tions of the ligand IGF-1 were shown to inhibit apoptosis
caused by the EGFR antagonist erlotinib, possibly due to
an increased reliance on the IGF-1R/PI3K signaling axis.
Interestingly, while IGF-1R can promote EMT-like
transitions it appears to be less frequently used by mes-
enchymal-like carcinoma cells as a sole driver of the PI3
kinase pathway. IGF-1R activation drives upregulation of
the PI3K-Akt survival pathway and promotes epithelial-to-
mesenchymal transition, and these changes may account
for the reduced cellular sensitivity to EGFR antagonists.
However, committed mesenchymal-like NSCLC, colon
and pancreas adenocarcinomas are not dependent on IGF-
1R for proliferation or survival [75], suggesting that, like
EGFR, IGF-1R signaling is an important driver in epithe-
lial cells and can promote EMT, but once these cells have
transitioned to a mesenchymal state they are no longer
reliant on IGF-1R. This hypothesis would suggest that the
combination of an EGFR antagonist such as erlotinib and
an inhibitor of IGF-1R could synergistically inhibit pro-
liferation and potentially drive apoptosis in early stage
tumors with an epithelial phenotype. Several in vitro
studies have provided data which supports this hypothesis
[86, 88–91]. Furthermore, since blockade of either IGF-1R
[92, 93] or EGFR [94–96] signaling results in decreased
metastasis in vivo, partnering EGFR and IGF-1R antago-
nists might also improve overall patient survival in early
disease in epithelial tumors dependent on EGFR and
IGF1R signaling.
Once a cancer cell has transitioned to a mesenchymal-
like phenotype, cellular dependence on IGF-1R and EGFR
signaling is reduced and alternate growth factor pathways
are activated. Recent data suggest that EMT-like transi-
tions can promote the novel acquisition of alternate
receptor tyrosine kinase (RTK) autocrine and paracrine
loops [97], such as PDGFR, which can exert proliferative
and anti-apoptotic actions. PDGFRa and b are restricted to
cells of mesodermal origin [98] and autocrine PDGFR
signaling has been described in non-epithelial tumors such
as gliomas [99, 100]. However high expression has been
observed in multiple tumor types including ovarian [101]
prostate [102] and breast [103] carcinomas, suggesting that
PDGFR may be detectable in stroma and in tumor cells
which have undergone EMT. Autocrine PDGFR expression
has been shown to promote progression of breast and
ovarian cancer and contribute to maintenance of a mes-
enchymal-like cell phenotype [101, 103, 104]. Thus,
mesenchymal cells which have acquired alternate signaling
pathways, such as PDGFR, to activate PI3K signaling and
prevent apoptosis may be sensitized to speciﬁc molecular
targeted therapies. The acquisition of these receptor sig-
naling pathways which are predominantly used in
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required signaling nodes, although this remains to be
determined. Nevertheless, this observation provides sup-
port for rationally designed combinations of targeted
therapies to impede the complex, heterogeneous signaling
pathways that exist within a tumor.
In summary, we propose a model in which carcinomas
undergo an epithelial-to-mesenchymal-like transition,
potentially triggered by dysregulated growth factor sig-
naling or inﬂammation-mediated activation of the PI3
kinase and Ras pathways [105]. Tumor cells with a mes-
enchymal-like phenotype become less reliant on EGFR,
IGF-1R, Met and Ron signaling pathways. Over time,
mesenchymal-like tumor cells appear to become more
committed to a mesenchymal phenotype through epige-
netic changes and can upregulate alternate receptor
tyrosine kinase pathways as mechanisms for survival sig-
naling and escape from anoikis. The interactions of EGF
receptor signaling with other cellular pathways regulating
mitogenic, survival and migration cues has clinical impli-
cations as we try to identify and develop treatments which
not only target the primary tumor cells but also the mes-
enchymal-like cells deriving from EMT-like transitions
that can promote cancer metastasis and recurrence.
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